Literature DB >> 3998702

Fatal acute selenium toxicity.

P Pentel, D Fletcher, J Jentzen.   

Abstract

Selenium is used widely in industry and as a dietary supplement. Reports of acute selenium toxicity are infrequent, however, and the relationship of toxicity to selenium concentrations in blood and tissues has not been established. We describe a patient who died eight days after ingesting selenious acid in the form of gun blueing. The patient's clinical course demonstrated many of the features of inorganic selenium toxicity described in animals; hypotension as a result of both vasodilation and decreased cardiac output, adult respiratory distress syndrome, severe myopathy which contributed to respiratory failure, and a garlicky odor to the breath. Four days after ingestion the serum selenium concentration was twenty times normal and urinary excretion seventy times normal. Postmortem tissue selenium concentrations were up to 40 times normal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998702

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  3 in total

Review 1.  Selenium. Nutritional, toxicologic, and clinical aspects.

Authors:  A M Fan; K W Kizer
Journal:  West J Med       Date:  1990-08

2.  Effects of 14-day oral low dose selenium nanoparticles and selenite in rat-as determined by metabolite pattern determination.

Authors:  Niels Hadrup; Katrin Loeschner; Kasper Skov; Gitte Ravn-Haren; Erik H Larsen; Alicja Mortensen; Henrik R Lam; Henrik L Frandsen
Journal:  PeerJ       Date:  2016-10-20       Impact factor: 2.984

3.  Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.

Authors:  Torquil Watt; Per Cramon; Jakob Bue Bjorner; Steen Joop Bonnema; Ulla Feldt-Rasmussen; Christian Gluud; Jeppe Gram; Jane Lindschou Hansen; Laszlo Hegedüs; Nils Knudsen; Pernille Bach-Mortensen; Runa Nolsøe; Birte Nygaard; Flemming Pociot; Maria Skoog; Per Winkel; Ase Krogh Rasmussen
Journal:  Trials       Date:  2013-04-30       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.